SGMT 5.49 Sagimet Biosciences Inc.
| Range: | 2.13-20.71 | Vol Avg: | 1285828 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0 | Cap: | 0.17B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Jul 17 2023 | Empoloyees: | 8 | ||
| CUSIP: | 786700104 | CIK: | 0001400118 | ISIN: | US7867001049 | Country: | US |
| CEO: | Mr. David A. Happel | Website: | https://sagimet.com | ||||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Stock Details
Positive 0.29
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
- Treatment with denifanstat achieved statistically significant and clinically meaningful ...
globenewswire.com·Fri Oct 11 2024
Positive 0.26
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with...
globenewswire.com·Tue Oct 01 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow